🌊 Market Tide Weekly — BBOT Structural Deep Dive Behind the headlines: a filings‑driven look at BridgeBio Oncology Therapeutics’ 78.8% resale overhang, governance concentration, and leadership transition. Calm analysis, no hype — just structure, timing, and alignment.












